173 related articles for article (PubMed ID: 20937594)
1. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
2. Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.
Nguyen TD; Bordeau BM; Balthasar JP
Mol Cancer Ther; 2023 Nov; 22(11):1332-1342. PubMed ID: 37493255
[TBL] [Abstract][Full Text] [Related]
3. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action.
Cline EN; Li MH; Choi SK; Herbstman JF; Kaul N; Meyhöfer E; Skiniotis G; Baker JR; Larson RG; Walter NG
Biomacromolecules; 2013 Mar; 14(3):654-64. PubMed ID: 23391096
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial Biosynthesis of 3-
Liu Q; Wang Y; Xia X; Li Z; Li Y; Shen Y; Wang H
ACS Synth Biol; 2024 Mar; 13(3):721-727. PubMed ID: 38377312
[TBL] [Abstract][Full Text] [Related]
6. Bridging the maytansine and vinca sites: cryptophycins target β-tubulin's T5-loop.
Abel AC; Mühlethaler T; Dessin C; Schachtsiek T; Sammet B; Sharpe T; Steinmetz MO; Sewald N; Prota AE
J Biol Chem; 2024 May; ():107363. PubMed ID: 38735475
[TBL] [Abstract][Full Text] [Related]
7. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Oroudjev E; Lopus M; Wilson L; Audette C; Provenzano C; Erickson H; Kovtun Y; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2700-13. PubMed ID: 20937595
[TBL] [Abstract][Full Text] [Related]
8. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugate (ADC) clinical pipeline: a review.
Sassoon I; Blanc V
Methods Mol Biol; 2013; 1045():1-27. PubMed ID: 23913138
[TBL] [Abstract][Full Text] [Related]
11. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
Poon KA; Flagella K; Beyer J; Tibbitts J; Kaur S; Saad O; Yi JH; Girish S; Dybdal N; Reynolds T
Toxicol Appl Pharmacol; 2013 Dec; 273(2):298-313. PubMed ID: 24035823
[TBL] [Abstract][Full Text] [Related]
12. Maytansine.
Issell BF; Crooke ST
Cancer Treat Rev; 1978 Dec; 5(4):199-207. PubMed ID: 367597
[No Abstract] [Full Text] [Related]
13. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine: mechanisms of action and drug resistance.
Barok M; Joensuu H; Isola J
Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
[TBL] [Abstract][Full Text] [Related]
15. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
Wong DJ; Hurvitz SA
Ann Transl Med; 2014 Dec; 2(12):122. PubMed ID: 25568875
[TBL] [Abstract][Full Text] [Related]
17. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
19. Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats.
Shen BQ; Bumbaca D; Yue Q; Saad O; Tibbitts J; Khojasteh SC; Girish S
Drug Metab Lett; 2015; 9(2):119-31. PubMed ID: 26031461
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
